The Biotech Voyager

Kevin Walton, CEO of Baseimmune, joins Ben and Jeff to break down one of the most underappreciated problems in modern medicine: fibrosis. IPF alone carries a life expectancy of three to five years upon diagnosis, and despite decades of research only three drugs have been approved, none of which halt or reverse the disease. Kevin explains why every previous approach has failed, why fibrosis is a ne...

Welcome to the Biotech Voyager. It's the live show that covers what's next in biotech. Feel free to leave a comment, and we will get to it as quickly as we can.

Jonathan Cohen-Gold, CEO of Houdini Bio, joins Ben and Jeff to break down one of the most underappreciated problems in cell and gene therapy: cells don't like foreign DNA. When you deliver a therapeutic gene, the cell's innate immune system recognizes it as a threat and shuts it down. Houdini Bio's platform uses AI and proprietary Houdini elements, short 100 base pair sequences, to give the therap...

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.

Wesley Wierson and Alex Abel founded Leah Labs seven years ago around a pets-first model. When generative biology arrived, they designed something that no existing investor would fund. Animal investors won't back human-scale outcomes. Human investors won't back animal health companies. So VelociTx had to be built. Their CAR-T platform redesigns the transmembrane domain using a 2,000 de novo screen...

The biggest unsolved problem in cell therapy is donor variability. Why one patient's cells work and another's fail is a question the field still cannot answer. Alex Ward and Caelan Anderson, co-founders of Tolemy Bio, are building the intelligence layer that cell therapy has been missing. Their platform Orbit integrates all the process context around how cells are grown, managed, and manufactured...

Welcome to the Biotech Voyager. It's the live show that covers what's next in biotech. Today on the show: - 3 brand new startups in biotech that emerged from Stealth - 2 CEO interviews: one company is building a vaccine for tissue scarring, and the other, which just raised over $9M, turns solid tumors into therapeutic factories. Leave a comment if you have any questions - we try to get to them all...

This week, Innovian Space printed the first kidney and liver constructs in human history on the International Space Station. Jana Studemeier, CCO at Innovian Space, joins The Biotech Voyager to explain why gravity is the single biggest obstacle to printing functional organs, why microgravity solves it, and how the cost of a space experiment is nothing compared to the cost of a failed clinical tria...

Jay Kaplan, co-founder of Fractyl Health, joins The Biotech Voyager to explain why current GLP-1 drugs like Ozempic might have a worthy successor: a gene therapy that delivers GLP-1 directly to the pancreatic beta cells, only when you eat. Their lead program Rejuva-001 is already outperforming today's best pharmacology in animal models and has received first approval to begin clinical studies in t...

YouTube Description: Non-viral gene delivery has always had one fatal flaw: it couldn't get DNA into the nucleus efficiently. LNPs top out at around 5% nuclear entry. SonoThera just hit 50% using ultrasound. Co-founder Ken Greenberg joins the show to break down exactly how they did it. We also cover AstroRx's embryonic stem cell-derived astrocyte therapy for MS, ANACA's TCR-T cell approach for sol...

Welcome to The Biotech Voyager. It's the live show that covers where the puck is going in biotech.

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.

Welcome to The Biotech Voyager - it's the show that covers what's next in biotech.

The Biotech Voyager is the show that covers what's next in biotech.

The live show that covers what's next in biotech. Join us live!

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.

ASGCT week moved fast. Too fast. So we’re doing a live aftershow on Monday, 11 AM to 12:30 PM EST to break down what happened at ASGCT 2026, the key insights, what surprised us, and what to watch next. Since this is a special one-off event, we will also stream this one live on Linkedin. We'll also have a special guest... so stay tuned. Come hang out with us. Add in your takeaways. See you there!

The Biotech Voyager is going live from 28 Capital's Back Bay offices on Monday to set the stage for ASGCT. We'll be covering the sessions, posters, and conversations worth your time this year, with guest appearances from NanoMosaic and Precede Bio sharing what they're bringing to the meeting. If you're heading to ASGCT or following from afar, tune in for a focused primer before the chaos begins.

Huge stories shaping the future of medicine this week. Researchers are using ultrasound to deliver gene therapy, bypassing traditional delivery methods entirely. Epigenetic editors are offering a new way to modify gene expression without cutting DNA. And a company developing gamma delta T cell engagers just closed an $83M Series A, a massive bet on a less explored branch of cancer immunotherapy. B...

Diaconos Oncology just released new data in pancreatic cancer, one of the deadliest and hardest-to-treat cancers on the planet. But their approach isn't a typical drug. Ben and Jeff break down how dendritic cell vaccines work, why conventional cancer vaccines keep falling short, and what makes this approach different. Plus, RNA exon editing technology that rewrites disease at the RNA level without...

In vivo CAR-T keeps stacking wins, AI quietly invades the operating room, and cancer vaccines stage their second act... plus, John Boyce from 28 Capital joins the show. The show will break down the in vivo CAR-T streak that's reshaping how the industry thinks about cell therapy economics, dig into where AI is actually showing up in surgical workflows (and where the hype outpaces the data), and unp...

Asgard's AT-108 might be the most insane immunotherapy of 2026. .. a first-in-class in vivo cell reprogramming play for cancer. Meanwhile, CNS gene therapy is having a moment: AviadoBio is crossing the blood-brain barrier, Avista's AI-designed capsids are heading to the eye and CSF, and Tenaya just dropped one-year cardiac gene therapy data at ASGCT. Plus: Dr. Nicole Paulk joins live! Her work on...